Atrial fibrillation and stroke prevention: Is warfarin still an option? - No

Journal of Neural Transmission

Volumn 120, Issue 10, 2013, Pages 1453-1456

  Ranganathan, R Lakshmi Narasimhan ^a   Venkatesh, P ^a  

^a Institute of Neurology   (India)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Newer anticoagulants; Rivaroxaban; Warfarin

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; APIXABAN; BETRIXABAN; DABIGATRAN; EDOXABAN; FLOVAGATRAN; IDRAPARINUX; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; ODIPARCIL; OTAMIXABAN; PEGMUSIRUDIN; RIVAROXABAN; RODENTICIDE; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; FOLLOW UP; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; STROKE; WARFARIN;

EID: 84885432191     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0943-3     Document Type: Article

References (11)

1. (2012) RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed RE-LY trial. ClinicalTrials.gov NCT00808067 (to be published)
2. Bousser MG, Bouthier J, Büller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Thorp-Pedersen C, Wyse DG (2008) Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371:315-321
3. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419-1426
4. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157:805-810
5. Ferro D, Loffredo L, Polimeni L et al (2007) Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2:24-28
6. Lopes RD, Alexander JH, Al-Khatib SM et al (2010) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159:331-339
7. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 362:1691-1698
8. Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883-891
9. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635-641
10. Stafford RS, Singer DE (1998) Recent national patterns of warfarin use in atrial fibrillation. Circulation 97(13):1231-1233
11. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983-988